Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Jiuxin Qu; Chi Wu; Xiaoyong Li; Guobin Zhang; Zhaofang Jiang; Xiaohe Li; Qing Zhu; Lei Liu

doi:10.1093/cid/ciaa489

Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clin Infect Dis. 2020 Nov 19;71(16):2255-2258. doi: 10.1093/cid/ciaa489.

Authors

Jiuxin Qu¹, Chi Wu¹, Xiaoyong Li¹, Guobin Zhang¹, Zhaofang Jiang¹, Xiaohe Li², Qing Zhu¹, Lei Liu³

Affiliations

¹ Department of Clinical Laboratory, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China.
² Department of Infectious Diseases, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China.
³ The Third People's Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China.

Abstract

We profiled the serological responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein and spike (S) glycoprotein. The majority of the patients developed robust antibody responses between 17 and 23 days after illness onset. Delayed, but stronger, antibody responses were observed in critical patients.

Keywords: COVID-19; IgG; IgM; SARS-CoV-2; serologic responses.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Viral / blood*
COVID-19 / diagnosis
COVID-19 / immunology*
COVID-19 Testing
China
Female
Hospitalization
Humans
Immunity, Humoral
Immunoglobulin G / blood*
Immunoglobulin M / blood*
Male
Middle Aged
SARS-CoV-2

Substances

Antibodies, Viral
Immunoglobulin G
Immunoglobulin M